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factor which induces the expression of various cellular antioxidant
and detoxifying enzymes through the binding and transcriptional
activation of antioxidant response elements (ARE) in the pro-
moters of their genes. The Nrf2/ARE pathway is known to protect
cells against various stress stimuli, primarily oxidative stress asso-
ciated with increased production of reactive oxygen species
(ROS). Nrf2 activity is tightly regulated by a cytoplasmic inhibitory
protein Kelch-like ECH-associated protein-1 (Keap-1) which acts as
an adaptor between Nrf2 and cullin-3 ubiquitin ligase and pro-
motes rapid proteasomal degradation of Nrf2. Being a sensor of
various exogenous and endogenous electrophilic compounds and
ROS, Keap-1 undergoes conformational changes upon interaction
with such agents and this causes Nrf2 release from the complex, thus
allowing it to translocate to the nucleus and transactivate Nrf2-
responsive genes [see (Harder et al., 2015; Tebay et al., 2015) for recent
reviews].
In their study, Khan et al. (this issue) demonstrate that there is
also an alternative mechanism whereby the Nrf2/ARE pathway can
be activated in human leukemia cells performing oxidative phos-
phorylation (OXPHOS). The authors found that while OXPHOS re-
sults in increased generation of ROS, the induction of the “classical”
Nrf2-responsive genes encoding heme oxygenase-1 (HO-1) and
NAD(P)H:quinone oxidoreductase (NQO1) can also occur in a
ROS-independent manner. This was associated with a decrease in
Keap-1 mRNA levels, implying that lower protein levels of Keap-1
may facilitate stabilization of the de novo synthesized Nrf2 protein,
thus increasing the functional activity of the Nrf2/ARE pathway.
The data also show that the MAPK ERK5 is upregulated in this sys-
tem. This suggests that ERK5 kinase is responsible for the downreg-
ulation of Keap-1, which may be mediated by the downstream target
of ERK5, the transcription factor MEF2C. Khan et al. show that MEF2CDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.11.045.
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3′-untranslated region (3'UTR). Taken together, the results suggest
that downregulation of Keap-1 in leukemic cells performing
OXPHOS is mediated by the ERK5/MEF2/miR-23a signaling and
that the resulting stabilization of Nrf2 leads to the activation of the
Nrf2/ARE pathway, thus protecting the cells from the deleterious
effects of ROS.
The ﬁndings by Khan et al. are in line with the previously reported
ability of microRNAs to downregulate Keap-1 expression by targeting
the 3′-UTR of its mRNA in several types of cancer cells (Eades et al.,
2011; Kabaria et al., 2015; van Jaarsveld et al., 2013). Interestingly,
MEF2A and MEF2C were shown to positively regulate the expression
of different microRNAs, including miR-23a, in human vascular
smooth muscle cells undergoing oxidative stress-induced senes-
cence (Zhao et al., 2015) and in cardiac myocytes from mice with
myotonic dystrophy (Kalsotra et al., 2014), respectively. Therefore,
the ERK5/MEF2/miR-23a/Keap-1 axis may represent a key regulato-
ry pathway in a broad range of cell types under various pathological
conditions.
The importance of microRNAs in regulation of hematopoiesis and
its aberrations has been known for several years [e.g., (Schotte et al.,
2012)]. For instance Gocek et al. (2011) found that the upregulation
of miR-32 by 1,25-dihydroxyvitamin D3 in human myeloid leukemia
cells leads to the targeting of the pro-apoptotic protein Bim, and in-
hibition of cytarabine-induced apoptosis, the latter frequently the
result of excess generation of intracellular ROS. The report by Khan
et al. demonstrates the important connection between microRNAs,
Keap-1 and the alleviation of cellular oxidative stress. As such, it
may indicate one basis for the emergence of resistance to cytotoxic
chemotherapy of human neoplastic diseases. The novel, ERK5/
microRNA-dependent, mode of Keap-1 downregulation suggested
by this study adds to the reported mechanisms related to Keap-1
promoter hypermethylation and inactivating mutations that lead
to hyperactivation of Nrf2/ARE, and thus to tumorigenesis and
chemoresistance [e.g., (Zhang et al., 2010)]. In this scenario, anti-
sense oligonucleotides which block miR-23a expression can be devel-
oped as therapeutic agents to ﬁght consequences of the loss of function
of Keap-1.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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